Weak Jobs Report Lifts Nvidia, Nasdaq 100 to Record Highs: Stock Market Today
A weak September payrolls print pared bets on more Fed tightening, lifting both the Nasdaq 100 and Nvidia stock to record highs.
Stocks · News reference
Bill Clinton Sounds Alarm on HIV Funding: ‘Cheaper Medicines Mean Nothing If They Never Reach People’
Clinton warns abrupt HIV funding shifts could disrupt treatment and prevention, saying “a deadline isn’t a transition plan” and lives could be at risk.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
September Jobs Report Misses: US Economy Adds 29,000 Jobs
The U.S. added just 29,000 jobs in September vs. 90,000 expected. Unemployment rose to 4.2% and wage growth came in below the 3.2% forecast.
Gold ETFs Keep the Bid, but Investors Miss This Key Seasonality Pattern
Despite rising yields, gold ETF demand holds firm near multi-year highs. Explore why central bank buying keeps a $4,000 price floor.
Gold Is Defying 24-Year-High Treasury Yields. Will Gold ETFs Follow?
Gold is holding above $4,000 despite soaring Treasury yields. Here’s why falling rates could reignite demand for gold ETFs.
Eli Lilly Says FDA Approves Additional Indication For Jaypirca, Non-Covalent BTK Inhibitor, For Treatment Of Adult Patients With Previously Untreated Chronic Lymphocytic Leukemia Or Small Lymphocytic Lymphoma
Eli Lilly and Company (NYSE:LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved an additional indication for Jaypirca (pirtobrutinib, 100 mg & 50 mg tablets), a non-covalent Bruton
Novo Nordisk vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?
Novo Nordisk and Pfizer are compared as pharmaceutical giants navigating different challenges. Novo Nordisk boasts superior profitability with a 33% net margin and strong cash flow, but faces pricing pressures and competition in the GLP-1 weight-loss drug market. Pfizer trades at lower valuations and is improving net income through strategic acquisitions in oncology and obesity, though it faces significant patent cliffs through 2030. The article recommends Pfizer as the better buy in 2026 based on its value metrics and improving earnings trajectory.